Skip to Content Facebook Feature Image

Pope Leo XIV is set to enter a Rome hospital for removal of a lung nodule

News

Pope Leo XIV is set to enter a Rome hospital for removal of a lung nodule
News

News

Pope Leo XIV is set to enter a Rome hospital for removal of a lung nodule

2026-10-13 13:00 Last Updated At:13:11

VATICAN CITY (AP) — Pope Leo XIV was expected to be admitted to a Rome hospital Tuesday for the removal of a lung nodule in an operation experts say will determine whether the lesion is malignant and if other treatment is needed.

Leo has offered a rare level of transparency about the first publicly disclosed major health problem of his 17-month papacy. He revealed the discovery of the small, localized nodule during his Sunday noon prayer and announced that he would have it removed.

The Vatican said Leo would be admitted to the Gemelli hospital late Tuesday morning, but there was no immediate word on the timing of the operation itself.

The surgery, which is usually performed under general anesthesia, will require a weeklong hospital stay and the Vatican on Monday canceled all Leo’s audiences through Oct. 20.

“These are things that can be treated very well, if the words he used reflect the clinical situation,” said Dr. Lorenzo Spaggiari, director of thoracic surgery at the European Institute of Oncology, or EIO, in Milan, who is not involved in the pope’s care but knows the team at Gemelli.

Spaggiari said he expected the team at Gemelli would perform a biopsy to determine whether Leo has lung cancer followed by the removal of a section or lobe of the lung where the nodule is located.

Both could be done using robotic techniques, and could be performed consecutively, under the same anesthesia, with different specialist teams, Spaggiari said.

A sophisticated robotic bronchoscopy technology called ION allows a biopsy on nodules as small as 3 millimeters (1/10 inch) , Spaggiari said. Both the Gemelli and the EIO have the technology, which has been available in Italy for just two years.

Gemelli also has robotic surgical technology, allowing the operation to remove the nodule to proceed “using a minimally invasive technique,” he said.

The technique involves the surgeon making four small incisions in the chest through which the instruments of the so-called da Vinci robot are inserted, he said. The surgeon then controls the robotic arms looking at a screen providing high-definition, 3D views of the surgical site.

“It’s a very well-established technology. This is something we have been doing for 20 years,” he said.

It wasn't known for certain what technique would be used on Leo. Gemelli has documented using both robotic procedures to diagnose and operate in under four hours.

The biopsy risk is “virtually zero,” while the surgical risk is very small, carrying a 0.6% to 0.8% mortality rate for patients in otherwise good health with good heart and lung function, Spaggiari said.

During the surgery to remove the nodule and part of the lung, doctors would also remove lymph nodes that drain the segment or lobe. “If all those lymph nodes turn out to be negative, so stage one, then the outlook is very good,” he said, adding that no other treatment would be necessary.

The nodule was discovered during regular checks, the Vatican has said, and Spaggiari said the pope has likely undergone other tests before being recommended for surgery.

“I think he has had a bit of luck. They found something that was asymptomatic — a lung nodule, possibly a tumor. He might call it something else; we call it luck,” he said.

EIO advises patients not to fly for three weeks after surgery — which would give the pope just the interval needed to make his planned Nov. 6-17 trip to Peru, Argentina and Uruguay, depending on his recovery.

“I think the Holy Father is in excellent hands at Gemelli,” Spaggiari said. “They have everything needed to keep the Holy Father alive for a long time.”

Leo’s surgery marks the first major health event of his pontificate. It was significant because the pope himself revealed the news, in perhaps the most public way possible: at the end of his Sunday noon blessing, with thousands of people in St. Peter’s Square.

The Vatican has for centuries zealously guarded the pope’s health and has often sent out confusing information, or none at all, about papal illnesses. Pope Francis tried to change that by being upfront about his frailties and musing on his eventual death. But even during his pontificate, information was tightly controlled.

Leo’s decision and reveal suggested an unusual level of transparency by the American pope.

“I really appreciated yesterday at the end of the Angelus, he himself said, ‘This is what’s going on — very transparent — and ask for prayers,’” said Quebec Cardinal Gérald Cyprien Lacroix at the Vatican Monday.

A lung nodule is a small abnormal area measuring less than 3 centimeters (1.2 inches) that sometimes appears on a CT scan of the chest or abdomen. Often, the scans are done to investigate trauma or a lung infection, unrelated to a lung cancer screening. A nodule can be benign or malignant, and oftentimes surgical removal is recommended both to establish whether it is cancer and to treat a malignancy while it is still localized.

Oncologists say even if the nodule turns out to be cancerous, Leo’s prognosis is “excellent” since it will have been removed at an early stage.

Barry reported from Milan.

Associated Press religion coverage receives support through the AP’s collaboration with The Conversation US, with funding from Lilly Endowment Inc. The AP is solely responsible for this content.

Pope Leo XIV leaves at the end the Angelus prayer in St. Peter's Square at the Vatican, Sunday, Oct. 11, 2026. (AP Photo/Gregorio Borgia)

Pope Leo XIV leaves at the end the Angelus prayer in St. Peter's Square at the Vatican, Sunday, Oct. 11, 2026. (AP Photo/Gregorio Borgia)

The statue of late Pope John Paul II is pictured at the Agostino Gemelli Polyclinic in Rome, Sunday, Oct. 11, 2026. (AP Photo/Gregorio Borgia)

The statue of late Pope John Paul II is pictured at the Agostino Gemelli Polyclinic in Rome, Sunday, Oct. 11, 2026. (AP Photo/Gregorio Borgia)

A mosaic of Pope Leo XIV is displayed inside a shop selling religious items near St. Peter's Square, in Rome, Monday, Oct. 12, 2026. (AP Photo/Gregorio Borgia)

A mosaic of Pope Leo XIV is displayed inside a shop selling religious items near St. Peter's Square, in Rome, Monday, Oct. 12, 2026. (AP Photo/Gregorio Borgia)

TSUBAME, Japan--(BUSINESS WIRE)--Oct 13, 2026--

TWINBIRD Corporation has announced the launch of the SC-UF25 Ultra-Low Temperature Portable Freezer, a compact 25-litre freezer capable of reaching temperatures as low as −86°C. Scheduled for release in November 2026, the new product expands the company’s line-up of solutions powered by its Free-Piston Stirling Cooler (FPSC) technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261012006333/en/

As life-science fields such as regenerative medicine, cell therapy and drug discovery continue to advance, reliable ultra-low-temperature management of research samples is becoming increasingly important. Although storage technologies have evolved, transport and temporary storage often depend on dry ice, posing challenges to temperature stability, operational efficiency and environmental impact. This has increased demand among researchers, laboratories and research organisations for sustainable cold-chain solutions that can maintain ultra-low temperatures from storage through to transport.

To address these challenges, TWINBIRD developed the SC-UF25 using its FPSC technology, which employs helium gas as a refrigerant. The freezer achieves temperatures down to −86°C while remaining compact and lightweight. It supports standard AC power input of 100–240 V, 50/60 Hz, enabling flexible use for stationary storage as well as transport within research facilities and between locations.

Key features include precise temperature control from −86°C to −20°C in 1°C increments, low-vibration and a compact design suitable for laboratories and research institutions where installation space is limited. The product also incorporates precision components manufactured in the renowned Tsubame-Sanjo region of Japan, drawing on advanced engineering expertise developed through decades of manufacturing excellence.

By enabling storage and transport in a −86°C environment, the SC-UF25 helps reduce dependence on dry ice while improving the stability and efficiency of ultra-low temperature cold-chain operations. Through the application of FPSC technology, TWINBIRD aims to support the preservation of high-value research materials and contribute to the advancement of life-science research and operations.

The SC-UF25 will be showcased at MEDICA 2026, one of the world’s largest trade fairs for the medical and life-science sectors, held in Düsseldorf, Germany, from 16 to 19 November 2026, where TWINBIRD will highlight the product’s contribution to sustainable ultra-low temperature cold-chain applications for research, laboratory and life-science use.

Disclaimer: The SC-UF25 is for research, laboratory and life-science cold-chain use only. It is not registered under the EU Medical Device Regulation and is not intended for diagnosis, treatment, clinical decisions, or patient care.

TWINBIRD Corporation Launches Ultra-Low Temperature Portable Freezer SC-UF25 to Enable a Dry-Ice-Free Cold Chain for Research Samples

TWINBIRD Corporation Launches Ultra-Low Temperature Portable Freezer SC-UF25 to Enable a Dry-Ice-Free Cold Chain for Research Samples

Recommended Articles